2023
Systematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Systematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma. Digestive And Liver Disease 2023, 55: s221. DOI: 10.1016/j.dld.2023.08.025.Peer-Reviewed Original ResearchChild-Pugh class B patientsClass B patientsDisease control rateObjective response rateImpaired liver functionB patientsHepatocellular carcinomaLiver functionChild-Pugh B cirrhosisTreatment-related adverse eventsHigher objective response rateAdverse events gradeBest supportive careMedian overall survivalProgression-free survivalIndividualization of treatmentClass AB cirrhosisChild-PughCohort studyFree survivalOverall survivalSupportive careAdverse eventsOncological efficacyAdherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatment
2011
Impact of HCV Infection on Graft Survival After Liver Transplantation for Hepatocellular Carcinoma in Compensated Cirrhosis: The Liver Match Cohort Study
Angelico M, Cillo U, Fagiuoli S, Strazzabosco M, Gasbarrini A, Romagnoli R, Nardi A. Impact of HCV Infection on Graft Survival After Liver Transplantation for Hepatocellular Carcinoma in Compensated Cirrhosis: The Liver Match Cohort Study. Gastroenterology 2011, 140: s-901. DOI: 10.1016/s0016-5085(11)63738-4.Peer-Reviewed Original ResearchOC-29 The allocation policy of liver grafts from HBcAb positive donors needs to be improved: Evidence from the Liver-Match cohort study
Marianelli T, Cillo U, Fagiuoli S, Prati D, Strazzabosco M, Gavrila C, Nardi A, Angelico M. OC-29 The allocation policy of liver grafts from HBcAb positive donors needs to be improved: Evidence from the Liver-Match cohort study. Digestive And Liver Disease 2011, 43: s74. DOI: 10.1016/s1590-8658(11)60030-3.Peer-Reviewed Original Research
2010
Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching
Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, Costa AN, Nardi A, Strazzabosco M, Burra P, Agnes S, Baccarani U, Calise F, Colledan M, Cuomo O, De Carlis L, Donataccio M, Ettorre GM, Gerunda GE, Gridelli B, Lupo L, Mazzaferro V, Pinna A, Risaliti A, Salizzoni M, Tisone G, Valente U, Rossi G, Rossi M, Zamboni F, Investigators O. Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching. Digestive And Liver Disease 2010, 43: 155-164. PMID: 21185796, DOI: 10.1016/j.dld.2010.11.002.Peer-Reviewed Original ResearchConceptsDonor risk indexObservational cohort studyHepatocellular carcinomaLiver transplantationCohort studyDonor ageVirus infectionDeceased heart-beating donorsHepatitis B core antibodyMedian cold ischaemia timeMedian donor risk indexProspective observational cohort studyEnd-stage liver diseaseHepatitis B virus infectionHepatitis C virus infectionLiver MatchDonor populationItalian transplant centersOlder donor ageViral-related cirrhosisB core antibodyC virus infectionStage liver diseaseB virus infectionHigh-risk donors